“Clinicians should be alert to that risk when prescribing ipratropium , especially for those receiving ipratropium more recently or those with concomitant use of SABAs or theophyllines.”
“Furthermore, an increased risk of stroke was found for ipratropium regimens involving concomitant use of inhaled short-acting β(2)-agonists ( SABAs ; adjusted OR, 2.18; 95% CI, 1.81 to 2.62) or theophyllines (adjusted OR, 1.79; 95% CI, 1.42 to 2.26).”